These results led the FDA in 2024 to approve Wegovy, initially green-lit for weight loss, for a second indication: to reduce the risk of serious heart problems in adults with cardiovascular disease who are overweight or have obesity
Understand the process, know your plan's limitations, and be prepared to advocate for yourself
Patient volumes for GLP-1s more than tripled between Q1 2020 and Q3 2022, yet only 57.0% of these patients had an official type 2 diabetes diagnosis
If you have a research idea or question, enroll in the registry or login and select "Submit a Research Question" from your registry home page
In other words, a healthy stomach produces, in very small amounts, this unique peptide, which helps keep the lining of the stomach intact